142 related articles for article (PubMed ID: 32313236)
1. Virtual biopsy using MRI radiomics for prediction of BRAF status in melanoma brain metastasis.
Shofty B; Artzi M; Shtrozberg S; Fanizzi C; DiMeco F; Haim O; Peleg Hason S; Ram Z; Bashat DB; Grossman R
Sci Rep; 2020 Apr; 10(1):6623. PubMed ID: 32313236
[TBL] [Abstract][Full Text] [Related]
2. Radiomics for the noninvasive prediction of the BRAF mutation status in patients with melanoma brain metastases.
Meißner AK; Gutsche R; Galldiks N; Kocher M; Jünger ST; Eich ML; Montesinos-Rongen M; Brunn A; Deckert M; Wendl C; Dietmaier W; Goldbrunner R; Ruge MI; Mauch C; Schmidt NO; Proescholdt M; Grau S; Lohmann P
Neuro Oncol; 2022 Aug; 24(8):1331-1340. PubMed ID: 34935978
[TBL] [Abstract][Full Text] [Related]
3. The significance of BRAF V600E mutation status discordance between primary cutaneous melanoma and brain metastases: The implications for BRAF inhibitor therapy.
Hannan EJ; O'Leary DP; MacNally SP; Kay EW; Farrell MA; Morris PG; Power CP; Hill ADK
Medicine (Baltimore); 2017 Dec; 96(48):e8404. PubMed ID: 29310328
[TBL] [Abstract][Full Text] [Related]
4. Predicting the BRAF mutation with pretreatment MRI radiomics features for melanoma brain metastases receiving Gamma Knife radiosurgery.
Kawahara D; Jensen A; Yuan J; Nagata Y; Watanabe Y
Clin Radiol; 2023 Dec; 78(12):e934-e940. PubMed ID: 37690975
[TBL] [Abstract][Full Text] [Related]
5. Radiomics of Pediatric Low-Grade Gliomas: Toward a Pretherapeutic Differentiation of
Wagner MW; Hainc N; Khalvati F; Namdar K; Figueiredo L; Sheng M; Laughlin S; Shroff MM; Bouffet E; Tabori U; Hawkins C; Yeom KW; Ertl-Wagner BB
AJNR Am J Neuroradiol; 2021 Apr; 42(4):759-765. PubMed ID: 33574103
[TBL] [Abstract][Full Text] [Related]
6. The
Angus L; Starmans MPA; Rajicic A; Odink AE; Jalving M; Niessen WJ; Visser JJ; Sleijfer S; Klein S; van der Veldt AAM
J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33915880
[TBL] [Abstract][Full Text] [Related]
7. Machine learning-based radiomics for predicting BRAF-V600E mutations in ameloblastoma.
Li W; Li Y; Liu X; Wang L; Chen W; Qian X; Zheng X; Chen J; Liu Y; Lin L
Front Immunol; 2023; 14():1180908. PubMed ID: 37646022
[TBL] [Abstract][Full Text] [Related]
8. A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.
Harding JJ; Catalanotti F; Munhoz RR; Cheng DT; Yaqubie A; Kelly N; McDermott GC; Kersellius R; Merghoub T; Lacouture ME; Carvajal RD; Panageas KS; Berger MF; Rosen N; Solit DB; Chapman PB
Oncologist; 2015 Jul; 20(7):789-97. PubMed ID: 25956405
[TBL] [Abstract][Full Text] [Related]
9. Radiomics features based on MRI predict BRAF V600E mutation in pediatric low-grade gliomas: A non-invasive method for molecular diagnosis.
Xu J; Lai M; Li S; Ye K; Li L; Hu Q; Ai R; Zhou J; Li J; Zhen J; Cai L; Shi C
Clin Neurol Neurosurg; 2022 Nov; 222():107478. PubMed ID: 36244075
[TBL] [Abstract][Full Text] [Related]
10. Identification of Multiclass Pediatric Low-Grade Neuroepithelial Tumor Molecular Subtype with ADC MR Imaging and Machine Learning.
Soldatelli MD; Namdar K; Tabori U; Hawkins C; Yeom K; Khalvati F; Ertl-Wagner BB; Wagner MW
AJNR Am J Neuroradiol; 2024 Jun; 45(6):753-760. PubMed ID: 38604736
[TBL] [Abstract][Full Text] [Related]
11. Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?
Yang L; Dong D; Fang M; Zhu Y; Zang Y; Liu Z; Zhang H; Ying J; Zhao X; Tian J
Eur Radiol; 2018 May; 28(5):2058-2067. PubMed ID: 29335867
[TBL] [Abstract][Full Text] [Related]
12. Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features.
Yue Q; Yu Y; Shi Z; Wang Y; Zhu W; Du Z; Yao Z; Chen L; Mao Y
J Neurosurg; 2018 Jul; 129(1):27-34. PubMed ID: 28984520
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Biomarker-Based BRAFV600 Mutation Association and Prediction in Melanoma.
Saadani H; van der Hiel B; Aalbersberg EA; Zavrakidis I; Haanen JBAG; Hoekstra OS; Boellaard R; Stokkel MPM
J Nucl Med; 2019 Nov; 60(11):1545-1552. PubMed ID: 31481581
[TBL] [Abstract][Full Text] [Related]
14. The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases.
Sperduto PW; Jiang W; Brown PD; Braunstein S; Sneed P; Wattson DA; Shih HA; Bangdiwala A; Shanley R; Lockney NA; Beal K; Lou E; Amatruda T; Sperduto WA; Kirkpatrick JP; Yeh N; Gaspar LE; Molitoris JK; Masucci L; Roberge D; Yu J; Chiang V; Mehta M
Int J Radiat Oncol Biol Phys; 2017 Aug; 98(5):1069-1077. PubMed ID: 28721890
[TBL] [Abstract][Full Text] [Related]
15. BRAF V600E mutation and BRAF kinase inhibitors in conjunction with stereotactic radiosurgery for intracranial melanoma metastases.
Xu Z; Lee CC; Ramesh A; Mueller AC; Schlesinger D; Cohen-Inbar O; Shih HH; Sheehan JP
J Neurosurg; 2017 Mar; 126(3):726-734. PubMed ID: 27203149
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
17. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
[TBL] [Abstract][Full Text] [Related]
18. Correlation of MRI signal characteristics of intracranial melanoma metastases with BRAF mutation status.
Lasocki A; McArthur GA
Melanoma Res; 2022 Oct; 32(5):373-378. PubMed ID: 35979667
[TBL] [Abstract][Full Text] [Related]
19. Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.
Gibney GT; Gauthier G; Ayas C; Galebach P; Wu EQ; Abhyankar S; Reyes C; Guérin A; Yim YM
Cancer Med; 2015 Aug; 4(8):1205-13. PubMed ID: 25991583
[TBL] [Abstract][Full Text] [Related]
20. Comparing BRAF mutation status in matched primary and metastatic cutaneous melanomas: implications on optimized targeted therapy.
Saroufim M; Habib RH; Gerges R; Saab J; Loya A; Amr SS; Sheikh S; Satti M; Oberkanins C; Khalifeh I
Exp Mol Pathol; 2014 Dec; 97(3):315-20. PubMed ID: 25236573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]